Terms: = Lung cancer AND HOXD13, SPD, 3239, P35453, HOX4I
153 results:
1. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
[TBL] [Abstract] [Full Text] [Related]
2. The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-cancer and Multi-Omics Analyses.
Chen M; Yan X; Hong B; Xiao Y; Qian Y
Int J Med Sci; 2024; 21(5):795-808. PubMed ID: 38616999
[No Abstract] [Full Text] [Related]
3. [lung-protective effect of esketamine combined with distal limb ischemic preconditioning in elderly patients undergoing thoracoscopic radical surgery for lung cancer: a randomized controlled trial in 160 cases].
Yang Y; Liu G; Ou Y; Lu W
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Mar; 44(3):484-490. PubMed ID: 38597439
[TBL] [Abstract] [Full Text] [Related]
4. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
Hayashi H; Chamoto K; Hatae R; Kurosaki T; Togashi Y; Fukuoka K; Goto M; Chiba Y; Tomida S; Ota T; Haratani K; Takahama T; Tanizaki J; Yoshida T; Iwasa T; Tanaka K; Takeda M; Hirano T; Yoshida H; Ozasa H; Sakamori Y; Sakai K; Higuchi K; Uga H; Suminaka C; Hirai T; Nishio K; Nakagawa K; Honjo T
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557498
[TBL] [Abstract] [Full Text] [Related]
5. cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract] [Full Text] [Related]
6. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract] [Full Text] [Related]
7. Cytokine and soluble programmed death-ligand 1 levels in serum and plasma of cancer patients treated with immunotherapy: Preanalytical and analytical considerations.
Cappelletto E; Fasiolo LT; Salizzato V; Piccin L; Fabozzi A; Contato A; Bianco PD; Pasello G; Chiarion-Sileni V; Gion M; Fabricio ASC
Int J Biol Markers; 2024 Mar; 39(1):9-22. PubMed ID: 38407953
[TBL] [Abstract] [Full Text] [Related]
8. Plasma spd-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X
Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011
[TBL] [Abstract] [Full Text] [Related]
9. spd-L1 and spd-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract] [Full Text] [Related]
10. Trans-Regulation of Alternative
Larsen TV; Maansson CT; Daugaard TF; Andresen BS; Sorensen BS; Nielsen AL
Cells; 2023 Dec; 12(24):. PubMed ID: 38132164
[TBL] [Abstract] [Full Text] [Related]
11. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.
Shimizu T; Inoue E; Ohkuma R; Kobayashi S; Tsunoda T; Wada S
Front Immunol; 2023; 14():1308381. PubMed ID: 38115995
[TBL] [Abstract] [Full Text] [Related]
12. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A; Huser J; Schmid S; Schär S; Scherz A; Gautschi O; Mauti L; von Briel T; Waibel C; Wannesson L; Pankovics J; Mark MT; Rothschild SI; Addeo A; Janthur WD; Siano M; Boos L; Britschgi C; Früh M
Lung Cancer; 2024 Jan; 187():107427. PubMed ID: 38043395
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Cui Q; Li W; Wang D; Wang S; Yu J
World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
[TBL] [Abstract] [Full Text] [Related]
14. The influence of plasma spd-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients.
Chmielewska I; Grenda A; Krawczyk P; Frąk M; Kuźnar Kamińska B; Mitura W; Milanowski J
Cancer Immunol Immunother; 2023 Dec; 72(12):4169-4177. PubMed ID: 37816808
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of soluble programmed death-1 ligand-1 of lung cancer patients with different characteristics.
Zhu HB; Song X
Eur Rev Med Pharmacol Sci; 2023 Sep; 27(18):8690-8696. PubMed ID: 37782182
[TBL] [Abstract] [Full Text] [Related]
16. Subcutaneous Leiomyosarcoma: An Aggressive Malignancy Portending a Significant Risk of Metastasis and Death.
Bresler SC; Gosnell HL; Ko JS; Angeles CV; Ronen S; Billings SD; Patel RM
Am J Surg Pathol; 2023 Dec; 47(12):1417-1424. PubMed ID: 37727934
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Cancer Immunol Immunother; 2023 Nov; 72(11):3755-3764. PubMed ID: 37646826
[TBL] [Abstract] [Full Text] [Related]
18. Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease.
Miller DL; Parks CS; Ange B; Bonta IR; Rich PT
J Surg Oncol; 2023 Sep; 128(4):604-611. PubMed ID: 37409778
[TBL] [Abstract] [Full Text] [Related]
19. Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.
Ancel J; Dormoy V; Raby BN; Dalstein V; Durlach A; Dewolf M; Gilles C; Polette M; Deslée G
Front Immunol; 2023; 14():1171649. PubMed ID: 37283751
[TBL] [Abstract] [Full Text] [Related]
20. Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.
Raza A; Mohsen R; Kanbour A; Zar Gul AR; Philip A; Vijayakumar S; Hydrose S; Prabhu KS; Al-Suwaidi AK; Inchakalody VP; Merhi M; Abo El-Ella DM; Tauro MA; Akbar S; Al-Bozom I; Abualainin W; Al-Abdulla R; Sirriya SA; Hassnad S; Uddin S; Mohamed Ibrahim MI; Al Homsi U; Demime S
Front Immunol; 2023; 14():1157100. PubMed ID: 37256148
[TBL] [Abstract] [Full Text] [Related]
[Next]
